RE:RE:RE:RE:We are calling the bottom: Analyst sees brighter outlookIts very rare to see a buy with a quadruple target especially given that other players are dismissed quite readily in the same report.So you have to ask why a potential entrant into the industry such as Big Pharma is going to watch while a company quadruples.